Insignia Systems Stock Surges 40%

Shares of nano-cap company Insignia Systems, Inc. (ISIG) surged nearly 40% on Wednesday morning despite no stock-related news to drive the shares. ISIG is currently trading at $12.26, up $3.50 or 39.92%, on the Nasdaq.

Insignia Systems provides in-store and digital advertising solutions to consumer-packaged goods manufacturers, retailers, shopper marketing agencies, and brokerages in the United States.

Stronghold Digital Mining Stock Tanks 32% On Q4 Results

Shares of Stronghold Digital Mining, Inc. (SDIG) tanked over 32% on Wednesday morning after the bitcoin mining company reported fourth-quarter results,

SDIG is currently trading at $6.95, down $3.30 or 32.22%, on the Nasdaq.

Net loss for the fourth quarter was $17.5 million compared to net income of $0.2 million for the same quarter a year ago. On a per share basis, the company reported loss of $0.52 per share.

Revenues in the fourth quarter increased to $17.0 million compared to $0.9 million in the same quarter a year ago. The increase is primarily attributable to higher energy generation and crypto asset mining revenues.

Analysts polled by Thomson Reuters expected earnings of $0.04 per share and revenues of $17.01 million for the quarter.

European Economics Preview: Germany Flash Inflation Data Due

Flash consumer prices from Germany and economic confidence from euro area are due on Wednesday, headlining a busy day for the European economic news.

At 2.00 am ET, Statistics Sweden releases retail sales for February. Sales had increased 4.5 percent on month in January.

At 3.00 am ET, Spain’s INE releases flash consumer and harmonized prices for March. EU harmonized inflation is forecast to rise to 8.1 percent from 7.6 percent in February.

In the meantime, the KOF leading index from Switzerland and economic tendency survey results from Sweden are due.

At 4.00 am ET, Italy’s Istat publishes business and consumer confidence survey data and producer prices.

At 5.00 am ET, the European Commission is slated to release Eurozone economic sentiment survey data. Economists expect the index to fall to 109.0 in March from 114.0 in February.

At 8.00 am ET, Destatis releases Germany’s flash CPI & HICP data. Consumer price inflation is seen at 6.7 percent in March versus 5.5 percent in February.

Paychex Adjusts Full Year Guidance Upward

Paychex, Inc. (PAYX) said, for fiscal 2022, the company now expects: adjusted earnings per share to grow in the range of 22.5% to 23%. Total revenue is now anticipated to grow in the range of 12% to 13%. Management Solutions revenue is now projected to grow in the range of 12% to 13%. In December, the company projected: adjusted earnings per share growth in the range of 18% to 20%; and total revenue increase in the range of 10% to 11%.

Paychex Inc. reported third quarter adjusted earnings per share of $1.15 compared to $0.96, prior year. Analysts on average had expected the company to earn $1.05 per share, according to figures compiled by Thomson Reuters. Analysts’ estimates typically exclude special items.

Net income was $430.7 million, or $1.19 per share compared to $350.5 million, or $0.97 per share, a year ago. Revenue rose 15.3% to $1.28 billion from $1.11 billion last year. Management Solutions revenue was $959.9 million, an increase of 13%.

Shares of Paychex were up 2% in pre-market trade on Wednesday.

CureVac, GSK Begin Clinical Trial For Second-Generation COVID-19 Vaccine Candidate, CV2CoV

German biopharmaceutical company CureVac N.V. (CVAC) announced Wednesday that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GlaxoSmithKline plc (GSK).

The clinical trial is expected to provide valuable data to further evaluate the performance of CureVac’s second-generation mRNA backbone, which has the potential to be applied broadly in future vaccines against COVID-19 variants and other pathogens.

The Phase 1 dose-escalation study is being conducted at clinical sites in the U.S. and is expected to enroll up to 210 healthy adults to evaluate the safety, reactogenicity and immunogenicity of CV2CoV in the dose range of 2 to 20µg. Data results from the Phase 1 study are expected in the second half of 2022.

Micron Technology Rises 3% On Higher Q2 Results Beating Estimates

Shares of Micron Technology, Inc. (MU) are up 3 percent on Wednesday’s trading, maintaining their upward trend since the past few days.

The stock has been positively impacted by the company reporting second-quarter earnings, which increased from last year and beat the Street estimates.

The company’s bottom line came in at $2.26 billion, or $2.00 per share. This compares with $0.60 billion, or $0.53 per share, in last year’s second quarter.

Excluding items, Micron Technology reported adjusted earnings of $2.44 billion or $2.14 per share for the period. Analysts on average had expected the company to earn $1.97 per share, according to figures compiled by Thomson Reuters.

The company’s revenue for the quarter rose 24.8 percent to $7.79 billion from $6.24 billion last year.

Currently at $85.13, the stock has traded between $65.67 and $98.45 during the past 52 days.

Biden to receive second COVID-19 booster shot on camera

Fox News Flash top headlines for March 30

Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.

President Biden is to receive his second COVID-19 booster shot on camera Wednesday. 

“Today, following his remarks on the status of the country’s fight against COVID-19, the President will receive his second COVID-19 booster shot,” the White House said in a statement. “The shot will be administered by a member of the White House Medical Unit.” 

President Biden receives a COVID-19 booster shot during an event in the South Court Auditorium on the White House campus, Monday, Sept. 27, 2021, in Washington.
(AP Photo/Evan Vucci)

This comes a day after the U.S. Food and Drug Administration on Tuesday authorized a second booster dose of either the Pfizer-BioNTech or the Moderna COVID-19 vaccines for older people and certain immunocompromised individuals. 

Biden received his first booster shot in September. The president was issued a third dose of the Pfizer-BioNTech COVID-19 vaccine on camera on Sept. 27, 2021.

This is a developing story. Check back for updates.